Advocate Kishan Sanmukhdas Bhawnani
India’s decision to tighten regulations governing the sale and distribution of cough syrups marks one of the most significant public health interventions in recent years. Through the Drugs (Fifth Amendment) Rules, 2026, notified on June 9, the Central Government has gone far beyond introducing a simple prescription requirement for certain medicines. The amendment represents a broader effort to strengthen drug safety, improve quality control, and restore confidence in India’s pharmaceutical ecosystem.
For decades, cough syrups and other liquid medicines have been among the most easily accessible healthcare products across the country. In many rural areas, they were available through local shops and informal vendors, often without prescriptions or professional supervision. While this accessibility served an important purpose in regions with limited healthcare infrastructure, it also created loopholes that encouraged misuse, unauthorized sales, poor quality control, and, in some cases, abuse of medicines containing habit forming ingredients.
The latest amendment seeks to address these concerns by removing the word “syrup” from the relevant entry in Schedule K of the Drugs Rules, 1945. This seemingly technical change has significant implications. Medicinal syrups, including cough syrups, will no longer enjoy the exemptions that previously allowed their sale under less stringent regulatory conditions in villages with populations below 1,000. Their distribution will now be confined to licensed pharmacies and authorized drug dealers operating within a regulated framework.
The move comes at a time when drug safety has become a global concern. In recent years, several countries reported tragic incidents involving the deaths of children linked to contaminated cough syrups. Investigations revealed the presence of toxic chemicals such as diethylene glycol and ethylene glycol in certain products. These incidents not only raised serious questions about medicine safety but also affected the reputation of India’s pharmaceutical industry, which supplies affordable medicines to much of the world.
Against this backdrop, the government’s response appears both necessary and timely. Public health cannot be compromised for the sake of convenience. Medicines that are consumed by millions, particularly children, must pass through robust systems of manufacturing, testing, certification, and distribution. Any weakness in this chain can have devastating consequences.
Importantly, the amendment is not confined to retail regulation. It is accompanied by broader reforms aimed at strengthening manufacturing standards. Revised provisions relating to Good Manufacturing Practices and Schedule M require pharmaceutical companies to adopt advanced quality management systems, risk assessment mechanisms, and stricter hygiene protocols. Mandatory testing for ethylene glycol and diethylene glycol in liquid medicines has also been introduced, significantly enhancing safeguards against contamination.
These measures align India’s pharmaceutical standards more closely with international best practices. They reinforce the principle that quality assurance must be embedded at every stage of production rather than treated as a final checkpoint before products enter the market.
Yet, every reform carries challenges, and this one is no exception. Millions of Indians continue to live in rural and remote areas where healthcare services remain inadequate. In many villages, licensed pharmacies are scarce and access to doctors is limited. For these communities, obtaining a prescription or travelling to a licensed outlet may involve additional costs, longer travel times, and considerable inconvenience.
The concern is genuine. Policymakers must ensure that stronger regulation does not inadvertently create barriers to essential healthcare. The solution lies not in weakening safety standards but in expanding healthcare access. The growth of telemedicine services, mobile health units, digital prescriptions, and licensed rural pharmacies can help bridge this gap while preserving the integrity of the regulatory system.
Another important objective of the amendment is the prevention of drug abuse. Certain cough syrups have long been misused for intoxicating purposes, particularly among adolescents and young adults. Easy availability without medical oversight contributed to this problem. By bringing these products under stricter control, the government hopes to reduce misuse and encourage responsible consumption.
Equally significant is the process through which the amendment was introduced. The government issued a draft notification in December 2025 and invited comments from stakeholders, including pharmaceutical companies, healthcare professionals, regulators, and members of the public. The final rules emerged after consultation with the Drugs Technical Advisory Board and consideration of feedback received during the consultation process. This lends credibility to the reform and reflects a measured approach rather than a sudden policy shift.
The Drugs (Fifth Amendment) Rules, 2026, therefore, should not be viewed merely as a restriction on cough syrup sales. They represent a broader transformation in India’s approach to pharmaceutical governance. The challenge ahead will be to ensure effective implementation while maintaining access to medicines for those living in underserved regions.
If executed properly, this reform could strengthen public trust, improve medicine safety, curb abuse, and enhance India’s standing as a reliable supplier of quality pharmaceuticals. In the long run, the temporary inconvenience faced by some consumers may prove a small price to pay for a safer and more accountable healthcare system.
(Advocate Kishan Sanmukhdas Bhawnani is a tax expert, columnist, literary writer, thinker, and social commentator based in Gondia, Maharashtra.)
